Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical
Read More
Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer, the US Food & Drug Administration (FDA) could soon be the next stop for biopharmaceuticals company Pharmaxis (ASX: PXS) fresh off their poster presentation at the American Society of Hematology (ASH) conference. Hosted in New
Read More
When it comes to biotech investing, the value opportunities in Australia attract many of the world’s smartest investors. Amongst them, Platinum Asset Management (ASX: PTM) has joined a growing list of institutions taking a substantial stake in a little-known Aussie biotech set to announce hugely-anticipated clinical trial results within the next few months. With more
Read More
More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is a progressive disorder which currently has no cure and few treatments. However, researchers at Parkinson’s UK have a new reason to hope. They are investigating whether early detection and treatment of certain sleeping disorders might
Read More
Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX: PXS) technology. In August, 2021 Aptar signed an exclusive option agreement to Pharmaxis’ “Orbital” technology, handing over USD $250,000. Now, a little under a year later, Aptar is deploying USD $2.5 million to exercise the
Read More